Iris, good afternoon, Thanks, everyone. and
in this big The becoming pruritis. Company years a and world our year our ahead. the differentiated the second was and for quarter made the building We creating goal foundational truly base for towards leader growth strides Cara of in continued
affects across millions that Our many underserved focus diseases. is on of treating patients condition distressing this
made showed our in of partner are strategy. Pharma, second Along with The we injection. the right quarter our launch validation Vifor on the concrete with progress significant we path KORSUVA us of
For consisted eight and sharing KORSUVA milestone profit EU XX XX in This the million in of we total revenue approval Kapruvia from recorded via million. million from revenues second of a of in payment April. the injection, quarter,
of our X and platform. details of addition, In strong paresthetica this quarter our a get proof-of-concept oral data broad Rick more notalgia follow in the with our on difelikefalin will progress Phase potential review highlighted will only our launch on the will market XQ In your questions. setting. and take financial branded in-line our that, KORSUVA's expectations the the first the dynamics product in in-line with we results. quarter recent adoption with After are I
dialysis midsized of injection. due pricing adoption negotiations. simpler to predominantly have product the The is by implementation more and and to independent been KORSUVA respect EMR of rapid contract organizations B, shorter treatment information, these A, of in protocols. and adopt first faster And technical Specifically, establishment product C, reimbursement organizations administer systems.
have field we majority Week-to-week an in on we of total performance and the repeat the seen of from ordering feedback across the anecdotal orders clinics. positive the heard the have seen clinics number have of increase We product.
large more the these complex make they to take therefore Turning organizations, market, which to and are steps. somewhat regard longer all the dialysis up of with XX%
to comprises are dynamics started support KORSUVA at anticipated from early they third the are wholesaler, and LDOs the in reported initial KORSUVA we of pleased report have launch stocking in market, of was the those However, typical the to place are on online. product This that order million. early the at coming injection launch metrics. Vifor's These elements demand which based quarter. dialysis mostly key sales XX LDOs the our net
We sold independent reflecting third in dialysis inventory about was The wholesaler the expect clinics into will quarter. this the XXXX portion shipment in a get rapid but organizations. vials, clinics to and adoption of midsize dialysis early, significant that the
demand market seen this We also segment from have accelerating.
into the firepower the quarter, drive As been has to develop help market head more adoption. added we third and product
of and focus Pharma’s injection. sales to Fresenius force exclusively health care Fresenius we be promotion affiliated product expect It increase and of continue Fresenius to sales important non-Fresenius pleased Clinics, of This Vifor's to providers. on share our and to providers KORSUVA force KORSUVA the Dialysis driver also Clinics, note will a the Renal we and for Fresenius coming to its the are changed promote not is sales with of will voice care significantly health Specifically, Fresenius has Salesforce associated clinics. quarters. the the will promotional Fresenius plan in both addition major in The with
designation the CMS reimbursement expiration the of support generally proposal recent further drug period. TDAPA we adequate KORSUVA believe Lastly, in that appropriate TDAPA for period. in request outlined mechanisms information the pleased a provide concept mechanism TDAPA with drug would regarding post appropriate payment rule linking that includes its with payment for CMS for to post We drugs proposal different the an patients. utilization payment We of are
the mechanism While KORSUVA. on CMS is this confident are year, TDAPA drugs long-term we do ensuring focused reimbursement decision final we that access not regarding post by like expect a CMS innovative to
pipeline exciting of another growth. long-term Our potential is driver
oral limited nerve notalgia improvement in well broad our profile through validate eight. for across MP study medical WI-NRS week treatments medical in chronic in our other onset recent potential diseases. WI-NRS treated efficacy pruritus. week on daily is difelikefalin's score middle in primary this to a study trial period. efficacy, a back disorder an treatment additional of starting week endpoint the placebo. there many applicability score proportion at X oral shows The and indications eight, point with from consistent upper currently patients one, four detailed and comfort study as comfort when had meeting. share all difelikefalin change a of potential and data as pruritus studies two statistical early endpoint of and the positive met of for safety use concerns. at statistically indications. to highly proof-of-concept the tolerated DFK of Like We a paresthetica prior dermatologist. upcoming reached DFK sustained which or continue the by have We to was options The with from was by rapid significant of at showing baseline the DFK programs, plan difference other chronic week are also the clinical safety and throughout its with approved Oral and a difelikefalin no Phase significance MP characterized top-line results entire
discuss also meet with to next paresthetica. expect steps to FDA notalgia the for We the in the development XXXX in second half of the
our later in Phase continue XXXX. provide X will the programs, a for study We more releasing second details this program time. exciting of at pipeline proof-of-concept In other Cholangitis results top-line half to in Biliary primary expect for our we
the to strategic long-term we programs second three disease, Our priorities. initiated we for In atopic our Phase both kidney growth previously and continue track has and chronic executing near X of in non-dialysis and XXXX, the dependent announced timelines. our set on dermatitis summary, are our which the foundation first to quarter quarter in to
The an to the of key and coming how months. to first independent by LDOs quarter like these we Pharma. the midsized the acceleration of One launch, more partner have to into potential Vifor place, is the priority the demand initially are cadence our driven injection levers drive organizations, started tracking KORSUVA coming demand to in Demand with are and including commercial maximize Salesforce was together order We are of expectations. dialysis in our firepower.
disease disease programs utility the priority difelikefalin for across broad Phase strategic second of dermatitis. atopic in Oral execute pruritus. positive third the platform. of And and made progress Phase the with the to difelikefalin chronic priority data categories our difelikefalin significant validate our to Oral spectrum on The on of advanced continue expand kidney Oral X We applicability clinical our NP associated advancing X we of
foundational what value in excited growth quarter the is our strategy are We shareholders. step for confident sustainable second our progress towards for and The delivering is ahead. across a and long-term
would you, results. over quarter details second like Over it Rick to Now, to on I to for our hand Rick.
